Literature DB >> 1907096

Enhanced expression of poly(ADP-ribose) synthetase gene in malignant lymphoma.

T Tomoda1, T Kurashige, T Moriki, H Yamamoto, S Fujimoto, T Taniguchi.   

Abstract

Over-expression of cellular protooncogenes has been proposed to function in the initiation and maintenance of malignancies. In order to distinguish malignant lymphoma from reactive proliferative diseases, we surveyed the expression levels of three protooncogenes(c-myc, c-fos and c-myb) in malignant lymphoma and reactive proliferative diseases. An increased level of c-myc or c-fos mRNA was observed in one case, respectively, out of three malignant lymphomata. The other cases exhibited no enhancement in protooncogenes. These oncogenes are critically regulated during differentiation, but the half-life of c-myc mRNA was very short, and the level of the mRNA decreased to the initial level very quickly. Thus, the high level of the expression of these oncogenes may not always be maintained in all malignant cells. We then examined the level of mRNA for poly(ADP-ribose) synthetase in those cases. An enhanced expression for the synthetase gene was observed in all five malignant lymphomata tested, but no increase in the level of the mRNA was observed in any reactive proliferative cases or normal lymph nodes. These results suggest that enhanced expression of poly(ADP-ribose) synthetase gene seems to be a common characteristic of protopathic malignant lymphoma. By using the characteristics of malignant lymphoma, the level of mRNA for the synthetase may be applicable for differential diagnosis of malignant lymphoma from several pathologically indistinguishable diseases.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1907096     DOI: 10.1002/ajh.2830370402

Source DB:  PubMed          Journal:  Am J Hematol        ISSN: 0361-8609            Impact factor:   10.047


  31 in total

1.  The ups and downs of DNA repair biomarkers for PARP inhibitor therapies.

Authors:  Xiaozhe Wang; David T Weaver
Journal:  Am J Cancer Res       Date:  2010-01-03       Impact factor: 6.166

2.  Population pharmacokinetic modeling of veliparib (ABT-888) in patients with non-hematologic malignancies.

Authors:  Ahmed Hamed Salem; Vincent L Giranda; Nael M Mostafa
Journal:  Clin Pharmacokinet       Date:  2014-05       Impact factor: 6.447

3.  Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer.

Authors:  Maha Hussain; Michael A Carducci; Susan Slovin; Jeremy Cetnar; Jiang Qian; Evelyn M McKeegan; Marion Refici-Buhr; Brenda Chyla; Stacie P Shepherd; Vincent L Giranda; Joshi J Alumkal
Journal:  Invest New Drugs       Date:  2014-04-26       Impact factor: 3.850

4.  The PARP Inhibitor Veliparib Can Be Safely Added to Bendamustine and Rituximab and Has Preliminary Evidence of Activity in B-Cell Lymphoma.

Authors:  Jacob D Soumerai; Andrew D Zelenetz; Craig H Moskowitz; M Lia Palomba; Paul A Hamlin; Ariela Noy; David J Straus; Alison J Moskowitz; Anas Younes; Matthew J Matasar; Steven M Horwitz; Carol S Portlock; Jason A Konner; Mrinal M Gounder; David M Hyman; Martin H Voss; Matthew G Fury; Devika Gajria; Richard D Carvajal; Alan L Ho; Jan H Beumer; Brian Kiesel; Zhigang Zhang; Alice Chen; Richard F Little; Christine Jarjies; Thu O Dang; Fallon France; Nishant Mishra; John F Gerecitano
Journal:  Clin Cancer Res       Date:  2017-03-17       Impact factor: 12.531

5.  Phase I/Ib study of olaparib and carboplatin in BRCA1 or BRCA2 mutation-associated breast or ovarian cancer with biomarker analyses.

Authors:  Jung-Min Lee; John L Hays; Christina M Annunziata; Anne M Noonan; Lori Minasian; Jo Anne Zujewski; Minshu Yu; Nicolas Gordon; Jiuping Ji; Tristan M Sissung; William D Figg; Nilofer Azad; Bradford J Wood; James Doroshow; Elise C Kohn
Journal:  J Natl Cancer Inst       Date:  2014-05-19       Impact factor: 13.506

6.  Expression of PARP-1 and its active polymer PAR in prostate cancer and benign prostatic hyperplasia in Chinese patients.

Authors:  Wenqi Wu; Hanliang Zhu; Yeping Liang; Zhenzhen Kong; Xiaolu Duan; Shujue Li; Zhijian Zhao; Dong Yang; Guohua Zeng
Journal:  Int Urol Nephrol       Date:  2014-01-17       Impact factor: 2.370

7.  Simultaneous determination of ABT-888, a poly (ADP-ribose) polymerase inhibitor, and its metabolite in human plasma by liquid chromatography/tandem mass spectrometry.

Authors:  Richard Wiegand; Jianmei Wu; Xianyi Sha; Patricia LoRusso; Jing Li
Journal:  J Chromatogr B Analyt Technol Biomed Life Sci       Date:  2009-11-27       Impact factor: 3.205

8.  Concurrent Veliparib With Chest Wall and Nodal Radiotherapy in Patients With Inflammatory or Locoregionally Recurrent Breast Cancer: The TBCRC 024 Phase I Multicenter Study.

Authors:  Reshma Jagsi; Kent A Griffith; Jennifer R Bellon; Wendy A Woodward; Janet K Horton; Alice Ho; Felix Y Feng; Corey Speers; Beth Overmoyer; Michael Sabel; Anne F Schott; Lori Pierce
Journal:  J Clin Oncol       Date:  2018-03-20       Impact factor: 44.544

9.  Poly(ADP-ribose) polymerase-1 polymorphisms, expression and activity in selected human tumour cell lines.

Authors:  T Zaremba; P Ketzer; M Cole; S Coulthard; E R Plummer; N J Curtin
Journal:  Br J Cancer       Date:  2009-06-30       Impact factor: 7.640

10.  PARP-1 Val762Ala polymorphism is associated with reduced risk of non-Hodgkin lymphoma in Korean males.

Authors:  Xue Mei Jin; Hee Nam Kim; Il-Kwon Lee; Kyeong-Soo Park; Hyeoung-Joon Kim; Jin-Su Choi; Sang Woo Juhng; Chan Choi
Journal:  BMC Med Genet       Date:  2010-03-03       Impact factor: 2.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.